Drug Detail:Teprotumumab (Teprotumumab [ tep-roe-toom-ue-mab ])
Drug Class: Growth hormone receptor blockers
Usual Adult Dose for Graves' Ophthalmopathy
Initial dose: 10 mg/kg intravenously
Maintenance dose: 20 mg/kg intravenously every 3 weeks for 7 additional infusions
Use: Treatment of thyroid eye disease
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 18 years.
This drug is not recommended for use in children.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Administer diluted solution over 90 minutes for the first 2 infusions; if well tolerated may reduce infusion time to 60 minutes for remaining infusions (if not well tolerated, continue 90 minute infusions).
- Do not administer via intravenous push or bolus.
Storage requirements:
- Refrigerate; do not freeze.
- Protect from light.
Reconstitution/preparation techniques: The manufacturer product information should be consulted.